Novartis AG · SIX:NOVN

Novartis — Q3 2000 Earnings Presentation

5 slides from Novartis's earnings presentation, 2000

  1. Slide 1: Nine Months 2000 Sales Background Information

    Nine Months 2000 Sales Background Information Investor Relations

  2. Slide 2: Pharmaceuticals Top 20 Products

    Pharmaceuticals Top 20 Products Sales Growth 9 Months ‘00 9 Months ‘00 Brands Market segment (CHF m) (% LC) Sandimmun® /Neoral® Transpl., RA, Psoriasis 1 555 - 4% Voltaren® Antirheumatic 1 029 -11% Lamisil® Fungal Infections 958 +11% Cibacen®/Lotensin® Antihypertensive 882 +25% of which Lotrel® 375

  3. Slide 3: Pharmaceuticals Top 20 Products

    Pharmaceuticals Top 20 Products Sales Growth 9 Months ‘00 9 Months ‘00 Brands Market segment (CHF m) (%LC) Leponex® /Clozaril® Schizophrenia 454 -8% Estraderm® Hormone replacement 318 +7% Nitroderm® Angina pectoris, CHF 267 -1% Foradil® Respiratory 247 +29% Sandoglobulin® Immunodeficiency syndromes

  4. Slide 4: Sales Performance of Recently Launched Pharmaceutical Products

    Sales Performance of Recently Launched Pharmaceutical Products Sales 9 Months ‘00 Brands Market segment (CHF m) Exelon® Alzheimer’s disease 124 Visudyne® * Macular degeneration 103 Trileptal® Epilepsy 89 Comtan® Parkinson’s disease 68 Simulect® Transplantation 40 Apligraf® Wound healing 14 * Booked

  5. Slide 5: Sales Third Quarter 2000

    Sales Third Quarter 2000 Q3 2000 Q3 1999 Change in local in CHF currencies CHF millions CHF millions % % Pharmaceuticals 4 492 3 9981 12 5 Generics 464 482 -4 -4 CIBA Vision 517 413 25 17 Consumer Health 1 582 1 4241 11 4 Animal Health 275 287 -4 -11 Continuing activities 7 330 6 604 11 4 Agribusine

Novartis — Q3 2000 Earnings Presentation on 6ix